SYS-CON MEDIA Authors: Mat Mathews, PR.com Newswire, David Smith, Tim Crawford, Kevin Benedict

News Feed Item

Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis

Editor Note: For more information about this release, please scroll to bottom.

LONDON, March 21, 2014 /PRNewswire/ --

The trading session on Thursday, March 20, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR) and Actavis PLC (NYSE: ACT). Free technical research on ZTS, MYL, AVNR and ACT can be downloaded upon signing up at:

http://www.investor-edge.com/398-register

On Thursday, Zoetis Inc.'s stock edged 0.60% higher, finishing the session at $30.09. The stock recorded trading volume of 3.67 million shares as compared to a three months average volume of 4.49 million shares. The stock fluctuated between $29.67 and $30.11 during the session. Shares of the company traded at a PE ratio of 22.09. Zoetis Inc.'s stock has advanced 2.42% in the previous three trading sessions and 0.40% in the last one month, while the same has declined 7.95% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. Zoetis Inc.'s 200-day moving average of $31.12 is above the 50-day moving average of $30.65. Moreover, the stock is trading at a Relative Strength Index (RSI) of 46.37. Sign up today to read free research on ZTS at:

http://www.investor-edge.com/398-ZTS-.pdf

Mylan Inc.'s stock reported a trading volume of 4.51 million shares, as compared with a three months average volume of 4.16 million shares. The stock ended the day at $52.61, down 1.29% and at an intraday range of $52.02 and $53.08. Shares of the company traded at a PE ratio of 28.50. Mylan Inc.'s shares have fallen by 1.70% in the previous three trading sessions, but they have advanced 0.67% in the last one month and 21.22% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. Mylan Inc.'s 50-day moving average of $48.67 is above the 200-day moving average of $40.15. Furthermore, the stock is trading at an RSI of 56.44. Sign up today to read free research on MYL at:

http://www.investor-edge.com/398-MYL-.pdf

On Thursday, shares in AVANIR Pharmaceuticals Inc. stock surged 3.24% to close at $4.14. A total of 1.82 million shares were traded, which is below the three months average volume of 2.38 million. The stock oscillated between $3.87 and $4.23 during the trading session. AVANIR Pharmaceuticals Inc.'s shares have gained 6.98% in the previous three trading sessions, 2.22% in the last one month, and 23.21% on YTD basis. The stock is trading above its 50-day moving average. AVANIR Pharmaceuticals Inc.'s 200-day moving average of $4.25 is trading above the 50-day moving average of $3.85. Furthermore, the stock is trading at an RSI of 49.10. Sign up today to read free research on AVNR at:

http://www.investor-edge.com/398-AVNR-.pdf

Actavis PLC's stock recorded a trading volume of 1.61 million shares, as compared with a three months average volume of 2.31 million shares. The stock ended the day at $215.72, down 0.35% after vacillating between $214.18 and $218.73. Shares of the company traded at a PE ratio of 62.43. Actavis PLC's shares have fallen by 2.11% in the last one month, but they have advanced 0.71% in the previous three trading sessions and 28.40% on YTD basis. Further, the company's stock is trading above its 50-day and 200-day moving averages. Actavis PLC's 50-day moving average of $198.51 is above the 200-day moving average of $156.53. Additionally, shares of the company are trading at an RSI of 57.82. Sign up today to read free research on ACT at:

http://www.investor-edge.com/398-ACT-.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.